3-hydroxybutyric acid has been researched along with Migraine Disorders in 3 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Emerging evidence suggest migraine is a response to cerebral energy deficiency or oxidative stress in the brain." | 3.30 | Defining metabolic migraine with a distinct subgroup of patients with suboptimal inflammatory and metabolic markers. ( Fischer, D; Gross, EC; Orsini, AL; Putananickal, N; Schoenen, J; Soto-Mota, A, 2023) |
| "The primary endpoint was the number of migraine days in the last four weeks of treatment, adjusted for baseline." | 3.11 | Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial. ( Cichon, S; Fischer, D; Gocheva, V; Gross, EC; Hafner, P; Henzi, BC; Nagy, S; Orsini, AL; Putananickal, N; Rubino, D; Sandor, P; Schmidt, S; Vogt, DR, 2022) |
| "Currently available prophylactic migraine treatment options are limited and are associated with many, often intolerable, side-effects." | 2.90 | Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial. ( Cichon, S; Fischer, D; Gross, E; Orsini, AL; Putananickal, N; Sandor, P; Schmidt, S; Vogt, DR, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Putananickal, N | 3 |
| Gross, EC | 2 |
| Orsini, AL | 3 |
| Schmidt, S | 2 |
| Hafner, P | 1 |
| Gocheva, V | 1 |
| Nagy, S | 1 |
| Henzi, BC | 1 |
| Rubino, D | 1 |
| Vogt, DR | 2 |
| Cichon, S | 2 |
| Sandor, P | 2 |
| Fischer, D | 3 |
| Schoenen, J | 1 |
| Soto-Mota, A | 1 |
| Gross, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety, Tolerability and Efficacy of Exogenous Ketone Bodies for Preventive Treatment of Migraine: A Randomised, Placebo-controlled, Double-blind Study[NCT03132233] | 42 participants (Actual) | Interventional | 2017-05-08 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for 3-hydroxybutyric acid and Migraine Disorders
| Article | Year |
|---|---|
Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial.
Topics: 3-Hydroxybutyric Acid; Cross-Over Studies; Double-Blind Method; Humans; Migraine Disorders; Treatmen | 2022 |
Defining metabolic migraine with a distinct subgroup of patients with suboptimal inflammatory and metabolic markers.
Topics: 3-Hydroxybutyric Acid; Brain; Humans; Migraine Disorders; Oxidative Stress; Patients | 2023 |
Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Analgesics; Biomarkers; Brain; Cross-Over Studies; D | 2019 |